KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Inventory (2016 - 2025)

Sarepta Therapeutics (SRPT) has 10 years of Change in Inventory data on record, last reported at -$18.5 million in Q4 2025.

  • For Q4 2025, Change in Inventory fell 111.43% year-over-year to -$18.5 million; the TTM value through Dec 2025 reached $301.1 million, down 23.81%, while the annual FY2025 figure was $301.1 million, 23.81% down from the prior year.
  • Change in Inventory reached -$18.5 million in Q4 2025 per SRPT's latest filing, down from $83.0 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $177.4 million in Q1 2025 and bottomed at -$18.5 million in Q4 2025.
  • Average Change in Inventory over 5 years is $48.9 million, with a median of $27.0 million recorded in 2021.
  • Peak YoY movement for Change in Inventory: soared 19675.16% in 2024, then crashed 111.43% in 2025.
  • A 5-year view of Change in Inventory shows it stood at $27.3 million in 2021, then tumbled by 67.43% to $8.9 million in 2022, then soared by 959.73% to $94.1 million in 2023, then skyrocketed by 71.79% to $161.7 million in 2024, then crashed by 111.43% to -$18.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Inventory were -$18.5 million in Q4 2025, $83.0 million in Q3 2025, and $59.2 million in Q2 2025.